AbbVie Resolves Humira (adalimumab) Litigation with Boehringer Ingelheim

 AbbVie Resolves Humira (adalimumab) Litigation with Boehringer Ingelheim

AbbVie Resolves Humira (adalimumab) Litigation with Boehringer Ingelheim

Shots:

  • AbbVie has resolved the Humira litigation with BI, granting BI non-exclusive rights to BI for Humira’s IPR in the US
  • BI will pay royalties for licensing HUMIRA patents and acknowledges the validity and enforceability of the licensed patents
  • The initiation of the license will begin from Jul,1 2023

Click here to read full press release/ article | Ref: AbbVie| Image: Modern Healthcare

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post